Laptop Battery By Lester Volt
laptop computers is driving strong sales for notebook computers, according to the latest quarterly sales figures from the research firm IDC, which reported a 37% computer sales for the second quarter, compared with a year earlier. In the U.S., laptop sales grew 17.7%, while sales of desktop computers and servers fell 4%. The New York Times ( 10), CNET ( 10)
Thinkpad Makers of arthritis biomarkers for the medical research
community, IBEX Technologies, Inc., reported a 12 percent increase
in revenue for the third quarter.If you would like to receive late
breaking news on health issues covered by AXcess News then you need
to subscribe.
We also cater to the adventure racer, adventure racing, those on active vacations, adventure travel, and shoppers who normally would have purchased polar fleece, but now understand the benefits of wearing Ibex Merino wool. Whether you are rock climbing, mountains climbing, or ice climbing, Ibex and Ibexwear has the outdoor clothing and gear you need.
Microsoft Print This Page
According to the indictment, Jones would steal various IBM and Penguin computer servers from Verisign's warehouse in Virginia and sell them to Johnson. Johnson would then sell the servers to several individuals, who would sometimes place them for sale on eBay. As a result of this scheme, the indictment alleges that Jones and Johnson caused Verisign to lose more than $120, 000 worth of computer equipment. In the indictment, Jones and Johnson are charged in three counts with causing the interstate transportation of stolen property, namely IBM 330 and 335 servers, in violation of 18 U.S.C.
Laptop Computers June 14, 2005 (AXcess News) Montreal, Quebec - Makers of
arthritis biomarkers for the medical research community, IBEX
Technologies, Inc. (TSX: IBT), reported a 12 percent increase in
revenue for the third
quarter."Sales of our arthritis biomarker
products to customers in the research community, including five
of the world's leading pharmaceutical
companies, are growing and we
look forward to building on our momentum as we continue to roll
out the next generation of our arthritis assays," said Paul
Baehr, President and CEO of IBEX.Revenue for the three-month
period ended April 30, 2005 increased 12% to $403,000 compared
to $359,000 in the third quarter of fiscal 2004. Sales of IBEX
Arthritis products increased 54% in the quarter compared to the
corresponding period a year ago, while the Company's enzyme
sales were down 12% versus the third quarter of fiscal 2004.
Revenue for the nine months ended April 30, 2005 increased 17%
to $1.1 million compared to $976,000 in the first nine months of
fiscal 2004.
Computer memory is the quickest, cheapest, and easiest way to improve the performance of your system. Find RAM memory upgrades for desktops, laptops, servers, and printers all backed by a lifetime warranty and guaranteed compatible with your computer. Shipping is an everyday low price of $1.99! Computer Memory Outlet sells memory compatible with all leading computer manufacturers like Dell, Apple, Compaq, HP, Sony, IBM, Lenovo, and many more.”
Laptop Computer Net loss for the third quarter of fiscal 2005 was $1.1 million
or ($0.05) per share, compared to a net loss of $871,000 or ($0.04)
per share in the third quarter a year ago. The Company's increased
net loss for the third quarter is primarily attributable to
increased selling, general, administrative and costs of goods sold
expenses, partially offset by decreased research and
development expenses. Net loss
for the nine months ended April 30, 2005 was $3.1 million or
($0.15) per share compared to a net loss of $2.7 million or
($0.13) per share in the first nine months of fiscal 2004.IBEX
is now selling four arthritis assays to the research community
for use in animal models to assist in the identification of
promising new drug candidates, and for use in human clinical
trials to assist in the selection of appropriate patients.
Revenue climbed 36 percent to $388.5 million from $285.3 million a year earlier. The Sunnyvale, Calif.-based company said net earnings in the latest quarter included a partial reversal of a deferred tax asset valuation allowance of about $13 million. For the fiscal fourth quarter ending June 2, Palm forecast revenue of $400 million to $405 million and adjusted earnings per share of 22 cents to 23 cents. Analysts, on average, have forecast revenue of $395.7 million and earnings per share before items of 21 cents.
Desktop Computer IBEX plans to release improved versions of its CP II and C2C
arthritis assays in the fourth quarter of calendar 2005. CPII
measures the synthesis of type II collagen and is initially
targeted for diagnosis of early rheumatoid arthritis. C2C is an
assay for the measurement of increased collagen degradation and is
initially targeted for osteoarthritis applications.During the third
quarter of fiscal 2005, IBEX re-negotiated the terms of its
kallikrein related May 2003 Share Purchase Agreement with the
former shareholders of Oncotherapeutics Inc. The new agreement
lowers the up front payments and replaces them with higher
downstream royalties. The consideration for this modification was
the issuance of 446,561 common shares valued at $150,000 and
$150,000 in cash.
Notebooks AXcess News interviewed IBEX's Baehr about its results, focusing
in on its arthritis biomarker market. When asked about its 54%
growth in that market Baehr was tight-lipped to name pharmaceutical
manufacturers that were delivering or developing arthritic drugs
due to the sensitivity of that information to the manufacturer.
Baehr expressly stated that many of the larger, well known, drug
companies that use IBEX's biomarker products do not want their work
exposed.
Lenovo But last year one of those larger drug companies did expose the
use of IBEX's biomarkers. Johnson & Johnson (NYSE: JNJ), who
disclosed their IBEX relationship in an American College of
Rheumatology write up.In late 2004, Pfizer, Inc. (NYSE: PFE)
announced that its arthritic drug, Bextra, had come under fire by
the FDA over risks of heart attack amongst patients that used it.
Baehr would not disclose if IBEX had a relationship with Pfizer,
though few products make it out of the research laboratories
without having used tools like those sold by IBEX.
Hard Drive Baehr had disclosed in the company's third quarter results
announcement that five major drug companies used IBEX's biomarkers.
Pfizer may be one of them, though Baehr would not comment.
Travelstar Baehr explained that the company was working on cancer assay
products that aide cancer researchers but that it was sensitive and
required more time to test and develop. That its cancer products
were exciting and held great potential to develop IBEX's sales.
Gateway Though IBEX is moving into a niche area that is sure to be
lucrative for the small biotech company, it appears to have enough
cash to get it there and with Baehr's tight-lipped response to our
questions regarding IBEX's arthritic biomarkers, it appears that
those products could lift IBEX out of its negative results before
its cancer assay biomarker products are ready for market, which
Baehr pegged to be sometime in 2007.AXcess News will be reporting
on any new trends related to this story. Members should watch their
in-box for late breaking news. If you're not a member, consider
joining now.
[ Comment, Edit or Article Submission ]
